Innogene Kalbiotech Pte. Ltd   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Bukit Batok Singapore (2003)
Status: Left NME R&D (2018)

Organization Overview

First Clinical Trial
2003
NCT00529490
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 4 Trials (2)

hydroxyethyl starch (voluven) (1 trial)

lactic acid (6 trials)

Drugs in Phase 3 Trials (4)

nimotuzumab (2 trials)

racotumomab (1 trial)

ringer's lactate (4 trials)

rituximab (rituxan) (1 trial)

Drugs in Phase 2 Trials (1)

cisplatin (platinol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Non-Small-Cell Lung (Phase 3)

Carcinoma, Squamous Cell (Phase 3)

Cardiac Output, Low (Phase 3)

Coronary Artery Disease (Phase 4)

Coronary Disease (Phase 4)

Dengue (Phase 3)

Head and Neck Neoplasms (Phase 2)

Heart Diseases (Phase 4)

Heart Failure (Phase 2)

Lung Neoplasms (Phase 3)

Lymphoma (Phase 3)

Lymphoma, B-Cell (Phase 3)

Lymphoma, Large B-Cell, Diffuse (Phase 3)

Myocardial Ischemia (Phase 4)

Neoplasms, Squamous Cell (Phase 2)

Severe Dengue (Phase 3)

Shock (Phase 3)

Shock, Hemorrhagic (Phase 3)

Squamous Cell Carcinoma of Head and Neck (Phase 3)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 7